Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Acute myeloid leukemia (AML) patients with t(8;21) aberration often have favorable outcomes, however, relapse still occurs in 30-40% patients, with only 50-60% of patients with t(8;21) AML cured with regimens containing high-dose cytarabine (HD-Ara-C). To evaluate the effects of fludarabine and cytarabine (FA) consolidation therapy for t(8;21) AML patients, a prospective randomized study was performed. A total of 45 patients with t(8;21) AML after achieving complete remission (CR) were randomly assigned to receive four course consolidation with FA (n = 23) or HD-Ara-C (n = 22). Our study showed that at 36-months, relapse-free survival (RFS) was 81.73% in the FA arm and 50.73% in the HD-Ara-C arm (P = 0.04), overall survival (OS) was 91.1% and 48.4% (P = 0.01) in the FA arm and in the HD-Ara-C arm respectively; whereas cumulative incidence of relapse (CIR) was 18.27% and 47.39%, in the FA arm and in the HD-Ara-C arm respectively (P = 0.05). In our study, treatment with FA, MRD2 status (reduction ≥ 3-log) and absence of c-kit mutations were identified as independent prognostic factors for lower risk of relapse, improved RFS and OS. We also found RFS for patients without c-kit mutations was 100% in FA arm, and 57.8% in HD-Ara-C arm at 36 months (P = 0.005); OS of both groups at 36 months was 100% and 51.4%, respectively (P = 0.004), suggesting a benefit of consolidation therapy with FA for t(8;21) AML patients, especially, those without c-kit mutations (Clinicaltrials.org ID NCT# 02024308). Am. J. Hematol. 92:12-17, 2017. © 2016 Wiley Periodicals, Inc.
Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, China.
Ruiqi
R
Li
Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, China.
Xiaoxia
X
Hu
Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, China.
Libing
L
Wang
Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, China.
Hui
H
Cheng
Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, China.
Shuqing
S
Lv
Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, China.
Weiping
W
Zhang
Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, China.
Jianmin
J
Wang
Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, China.
Jianmin
J
Yang
Department of Hematology, Institute of Hematology, Changhai Hospital, Shanghai, China.|Department of Hematology, Shanghai Jiao Tong University Affiliated First People's Hospital, Shanghai, China.
Xianmin
X
Song
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D060830:Consolidation Chemotherapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008875:Middle Aged; D009154:Mutation; D011446:Prospective Studies; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D014178:Translocation, Genetic; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D055815:Young Adult
D003561:Cytarabine; D019009:Proto-Oncogene Proteins c-kit; D014740:Vidarabine; C024352:fludarabine